Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PDK1
REST API REST API
Homo sapiens
PDK1 is differentially expressed in 282 experiments: 125 organism parts: adipose tissue, kidney, ... (123 more);, 152 disease states: normal, acute myeloid leukemia, ... (150 more);, 87 cell types 394 cell lines 34 compound treatments and 77 other conditions.
Orthologs PDK1 (Gallus gallus)   PDK1 (Bos taurus)   Pdk1 (Rattus norvegicus)   PDK1 (Danio rerio)   ENSCING00000001943 (Ciona intestinalis)   Pdk1 (Mus musculus)   PKP2 (Saccharomyces cerevisiae)   Pdk (Drosophila melanogaster)   pdk1 (Xenopus laevis)   PDK1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term glucose metabolic process, mitochondrial matrix, pyruvate dehydrogenase complex, ATP binding, peptidyl-histidine phosphorylation, small GTPase mediated signal transduction, cell surface receptor linked signaling pathway, protein heterodimerization activity, protein histidine kinase activity, two-component sensor activity, nucleotide binding, kinase activity, carbohydrate metabolic process, transferase activity, protein homodimerization activity, signal transduction, protein kinase activity, pyruvate metabolic process, pyruvate dehydrogenase (acetyl-transferring) kinase activity, mitochondrion, protein complex binding, protein phosphorylation, regulation of acetyl-CoA biosynthetic process from pyruvate
InterPro Term ATPase-like_ATP-bd, Sig_transdc_His_kinase_core, BCDHK/PDK_N
UniProt Accession Q15118, Q53R49, C9IYB4, C9JKT3, B7Z7N6, B7Z207, E9PD65, F8WEJ6, F8WC75
Search EB-eye ENSG00000152256
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-MEXP-1006, E-GEOD-19639, ... (41 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
A549
2
E-GEOD-6013, E-GEOD-3202
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
KG1
2
E-MTAB-37, E-GEOD-24147
NCI-H929
2
E-MTAB-62, E-MEXP-1269
388 more value(s).


Cell type

studied in E-GEOD-492, E-GEOD-22529, E-TABM-40, E-GEOD-22373, E-MEXP-2426, ... (47 experiments)

Factor Value U/D Experiments
adipocyte
2
E-AFMX-5, E-TABM-145
monocyte
1
2
E-GEOD-11755, E-GEOD-7307, E-GEOD-22373
T cell
1
E-GEOD-13987
adult native RPE from 76 y.o. donor
1
E-GEOD-18811
trabecular meshwork cell
1
E-GEOD-492
primary blood vessel endothelial cell
1
E-MEXP-66
81 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-MEXP-1121, E-GEOD-16363, E-GEOD-5370, ... (49 experiments)

Factor Value U/D Experiments
colon carcinoma
2
E-MTAB-62, E-MTAB-37
control
2
E-GEOD-21912, E-GEOD-20602
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
acute myeloid leukemia
1
2
E-MTAB-62, E-GEOD-995, E-MTAB-37
prostate carcinoma
1
2
E-MEXP-2034, E-MTAB-37, E-GEOD-96
lung large cell carcinoma
1
E-MTAB-62
146 more value(s).


Compound treatment

studied in E-GEOD-6907, E-GEOD-15205, E-TABM-782, E-GEOD-5824, E-TABM-868, ... (22 experiments)

Factor Value U/D Experiments
none
2
8
E-GEOD-5824, E-GEOD-20719, E-GEOD-2803, E-GEOD-412, E-TABM-868, ... (10 experiments)
lipopolysaccharide
2
E-TABM-868, E-MEXP-1958
PGE2
1
E-MEXP-1230
filtered air
1
E-TABM-127
unknown
1
E-GEOD-7307
platelet-derived growth factor
1
E-GEOD-1923
28 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (12 experiments)

Clinical info
studied in E-GEOD-2018, E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-5999, E-GEOD-1614, E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22148, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (7 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-GEOD-18005, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-22278, E-MEXP-445, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-GEOD-1926, E-MEXP-2069, ... (30 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-17400

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, E-GEOD-1460, ... (8 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-19069, E-GEOD-7540, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-13909, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-33562, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-6532, ... (6 experiments)

Processing time: 0.489 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM